SEC Comment Letter 0000000000-23-013011 to Cannabis Bioscience International Holdings, Inc. (CBIH)
Cannabis Bioscience International Holdings, Inc.
Date: Nov. 29, 2023 · CIK: 0001411057 · Accession: 0000000000-23-013011
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-267039
Letter
United States securities and exchange commission logo November 29, 2023 Dante Picazo Chief Executive Officer Cannabis Bioscience International Holdings, Inc. 6201 Bonhomme Road Suite 466S Houston, TX 77036 Re:Cannabis Bioscience International Holdings, Inc. Amendment No. 6 to Registration Statement on Form S-1 Filed November 13, 2023 File No. 333-267039 Dear Dante Picazo: We have reviewed your amended registration statement and have the following comments. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our October 19, 2023 letter. Amendment No. 6 to the Registration Statement on Form S-1, Filed November 13, 2023 Description of Business Clinical Trial in Which We Will be the Sponsor, page 58 1.We note your response to comment 2 and we reissue. In your response letter you state that the registration statement has been amended to state that you will not be selling any CBD products in the 18 states that restrict their sale and use. However, we do not see any such amendments in the registration statement; please make such amendment or advise us where the amendment was made.
FirstName LastNameDante Picazo Comapany NameCannabis Bioscience International Holdings, Inc. November 29, 2023 Page 2 FirstName LastName Dante Picazo Cannabis Bioscience International Holdings, Inc. November 29, 2023 Page 2 Item 16A. Exhibits Exhibit 23.1, page II-4 2.Please file an updated consent letter from PWR CPA, LLP that has a current date. Please contact Ta Tanisha Meadows at 202-551-3322 or Theresa Brillant at 202-551- 3307 if you have questions regarding comments on the financial statements and related matters. Please contact Nicholas Nalbantian at 202-551-7470 or Lilyanna Peyser at 202-551- 3222 with any other questions. Sincerely, Division of Corporation Finance Office of Trade & Services cc: Barry J. Miller
Show Raw Text
United States securities and exchange commission logo
November 29, 2023
Dante Picazo
Chief Executive Officer
Cannabis Bioscience International Holdings, Inc.
6201 Bonhomme Road
Suite 466S
Houston, TX 77036
Re:Cannabis Bioscience International Holdings, Inc.
Amendment No. 6 to Registration Statement on Form S-1
Filed November 13, 2023
File No. 333-267039
Dear Dante Picazo:
We have reviewed your amended registration statement and have the following
comments.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments. Unless we note otherwise,
any references to prior comments are to comments in our October 19, 2023 letter.
Amendment No. 6 to the Registration Statement on Form S-1, Filed November 13, 2023
Description of Business
Clinical Trial in Which We Will be the Sponsor, page 58
1.We note your response to comment 2 and we reissue. In your response letter you state that
the registration statement has been amended to state that you will not be selling any CBD
products in the 18 states that restrict their sale and use. However, we do not see any such
amendments in the registration statement; please make such amendment or advise us
where the amendment was made.
FirstName LastNameDante Picazo
Comapany NameCannabis Bioscience International Holdings, Inc.
November 29, 2023 Page 2
FirstName LastName
Dante Picazo
Cannabis Bioscience International Holdings, Inc.
November 29, 2023
Page 2
Item 16A. Exhibits
Exhibit 23.1, page II-4
2.Please file an updated consent letter from PWR CPA, LLP that has a current date.
Please contact Ta Tanisha Meadows at 202-551-3322 or Theresa Brillant at 202-551-
3307 if you have questions regarding comments on the financial statements and related
matters. Please contact Nicholas Nalbantian at 202-551-7470 or Lilyanna Peyser at 202-551-
3222 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Trade & Services
cc: Barry J. Miller